Allergy Therapeutics Sees Financial and Clinical Progress
Company Announcements

Allergy Therapeutics Sees Financial and Clinical Progress

Allergy Therapeutics (GB:AGY) has released an update.

Allergy Therapeutics has reported a financial recovery with an expected increase in H2 revenues to £21.6m, marking the first half-year growth since 2021, despite a full-year revenue decrease of 7%. Significant reductions in the company’s overheads have been achieved, and clinical advancements include successful trials for their Grass MATA MPL product and progress in their VLP Peanut vaccine trials. The company anticipates submitting a marketing authorization application for the Grass MATA MPL in Q4 2024, with ongoing shareholder support for funding requirements.

For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Sees Growth and Strategic Advances
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Shows Financial Turnaround and Clinical Progress
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Launches Pediatric Trial for Allergy Vaccine
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App